Effectiveness of Smartconsent in Improving Understanding of Informed Consent (SMARTCONSENT)
Benign Prostatic Hyperplasia
About this trial
This is an interventional other trial for Benign Prostatic Hyperplasia
Eligibility Criteria
Inclusion criteria:
- Patients willing to receive information via tablet.
- Patients who know and can read.
Exclusion Criteria:
- Not applicable
Sites / Locations
- Imanol Merino
- Bioaraba Health Research Institute
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
smartconsent group
control group
Intervention group: : the principal investigator upon receiving the tablet enters with his/her user and password, registers his/her signature, selects the patient (anonymized), selects the intervention and then the tablet will be given to the patient and he/she will be instructed to follow the indications in order to be able to project the video and digitally sign the informed consent.
Control group: The informed consent paper document (official format) will be printed with the patient's name, signed by the physician (principal investigator) and given to the patient to read and sign.